Billadeau D - Search Results

1

Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.

Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, Kyle RA, Oken MM, Van Ness B. Liu P, et al. Among authors: billadeau d. Blood. 1996 Oct 1;88(7):2699-706. Blood. 1996. PMID: 8839865 Free article. Clinical Trial.

2

Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients.

Billadeau D, Quam L, Thomas W, Kay N, Greipp P, Kyle R, Oken MM, Van Ness B. Billadeau D, et al. Blood. 1992 Oct 1;80(7):1818-24. Blood. 1992. PMID: 1391945 Free article.

3

Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease.

Billadeau D, Blackstadt M, Greipp P, Kyle RA, Oken MM, Kay N, Van Ness B. Billadeau D, et al. Blood. 1991 Dec 1;78(11):3021-9. Blood. 1991. PMID: 1954387 Free article.

4

Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma.

Billadeau D, Van Ness B, Kimlinger T, Kyle RA, Therneau TM, Greipp PR, Witzig TE. Billadeau D, et al. Blood. 1996 Jul 1;88(1):289-96. Blood. 1996. PMID: 8704185 Free article.

5

Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.

Billadeau D, Liu P, Jelinek D, Shah N, LeBien TW, Van Ness B. Billadeau D, et al. Cancer Res. 1997 Jun 1;57(11):2268-75. Cancer Res. 1997. PMID: 9187131

6

Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial.

Kay NE, Leong T, Kyle RA, Greipp P, Billadeau D, Van Ness B, Bone N, Oken MM. Kay NE, et al. Among authors: billadeau d. Blood. 1997 Jul 1;90(1):340-5. Blood. 1997. PMID: 9207470 Free article. Clinical Trial.

7

Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6.

Billadeau D, Jelinek DF, Shah N, LeBien TW, Van Ness B. Billadeau D, et al. Cancer Res. 1995 Aug 15;55(16):3640-6. Cancer Res. 1995. PMID: 7627974

8

Detection of B-cells clonally related to the tumor population in multiple myeloma and MGUS.

Billadeau D, Greipp P, Ahmann G, Witzig T, Van Ness B. Billadeau D, et al. Curr Top Microbiol Immunol. 1995;194:9-16. doi: 10.1007/978-3-642-79275-5_2. Curr Top Microbiol Immunol. 1995. PMID: 7895525 No abstract available.

9

The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell.

Billadeau D, Ahmann G, Greipp P, Van Ness B. Billadeau D, et al. J Exp Med. 1993 Sep 1;178(3):1023-31. doi: 10.1084/jem.178.3.1023. J Exp Med. 1993. PMID: 8350044 Free PMC article.

10

Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement.

Billadeau D, Prosper F, Verfaillie C, Weisdorf D, Van Ness B. Billadeau D, et al. Leukemia. 1997 Sep;11(9):1565-70. doi: 10.1038/sj.leu.2400773. Leukemia. 1997. PMID: 9305613 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

234 results

Search Page

Filters